| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4650 | sch-79687 | Novel histamine H3-receptor antagonist |
|
| DCC4651 | Sch-900822 | Novel potent and selective glucagon receptor antagonist |
|
| DCC4652 | Schembl12616233 | Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
| DCC4653 | Schembl1548848 | Novel inhibitor of vanilloid receptor subtype 1 (VR1) |
|
| DCC4654 | Schembl15939407 | Novel Lysine-Specific Demethylase 1 (LSD1) Inhibitor (IC50: 20nM) |
|
| DCC4655 | Schembl18320671 | Novel glucose transport inhibitor |
|
| DCC4656 | Schembl18616095 | Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
| DCC4657 | Schembl20148701 | Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
| DCC4658 | scio-469 Hydrochloride | Selective, ATP-competitive p38 |
|
| DCC4659 | Scq-14d | Novel Inhibitor of p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs) with the IC50 values of 140, 910 and 17.5 nmol/L against MDM2, HDAC1, and HDAC6, respectively, showing the tumor growth inhibition (TGI) in the A549 xenograf |
|
| DCC4660 | Scr1693 | Novel dual acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) |
|
| DCC4661 | Scr-4026 | Novel inhibitor of nNOS-PSD-95 interaction, exhibiting neuroprotective activities in NMDA-induced or Oxygen and glucose deprivation (OGD)-induced neuronal damage in primary cortical neurons cultures, and ameliorating focal cerebral ischemic damage in rats |
|
| DCC4662 | Scriptene | NRTI-drug pair of zidovudine (AZT)-didanosine (ddI), being highly cytotoxic and mutagenic |
|
| DCC4663 | S-cw3554 | Novel irriversible selective PDI inhibitor, selectively labeling protein disulfide isomerase and inhibiting its enzymatic activity, showing unique cytotoxicity in cells derived from multiple myeloma |
|
| DCC4664 | Sd2590 Hydrochloride | Potent inhibitor of MMP-2, -3, -9, -8, -13, and -14 |
|
| DCC4665 | Sdz 205-557 Hydrochloride | Selective, surmountable antagonist for 5-HT4 receptors |
|
| DCC4666 | Sdz 90-215 | Novel inhibitor of the Golgi complex (Vrg4); Antifungal |
|
| DCC4667 | Sdz Mrl 953 | Novel immunostimulatory monosaccharidic lipid A analog, down-regulating TNF-alpha and IL-6 production and priming secretion of G-CSF and IL-1 beta |
|
| DCC4668 | Sdz Ser 082 Fumarate | Selective 5-HT2B/2C receptor antagonist |
|
| DCC4669 | sdz-285604 | Novel inhibitor of sterol 14a-demethylases (CYP51) |
|
| DCC4670 | Sdz-lap-977 | Potent antiproliferative agent, binding to the “colchicine binding site” on tubulin and inhibiting tubulin polymerization in vitro |
|
| DCC4671 | sdz-nkt343 | Highly selective human tachykinin NK1 receptor antagonist |
|
| DCC4672 | Secologanate | Natural plant growth inhibitor |
|
| DCC4673 | Seco-rapamycin Ethyl Ester | Novel open-ring metabolite of rapamycin derivative |
|
| DCC4674 | Securinine Mononitrate | Antagonist of gamma-aminobutyric acid A (GABA A ) receptor and cholinergic agent |
|
| DCC4675 | Seh/ache Inhibitor 12c | Novel Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease |
|
| DCC4676 | Seh-in-12 | Novel potent inhibitor of the enzyme soluble epoxide hydrolase (sEH) |
|
| DCC4677 | Sempai | Novel AkaLumine analog, acting asa NIR emission luciferin with the enhanced solubility in water |
|
| DCC4678 | Sen205a | Novel S100B inhibitor |
|
| DCC4679 | Sen461 | Novel Wnt inhibitor/Axin stabilizer |
|
